Accuray Incorporated (NASDAQ:ARAY) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its position in Accuray Incorporated (NASDAQ:ARAY) by 28.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 212,330 shares of the medical equipment provider’s stock after buying an additional 47,331 shares during the quarter. Assenagon Asset Management S.A. owned about 0.21% of Accuray worth $420,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in shares of Accuray by 0.3% in the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after acquiring an additional 7,500 shares in the last quarter. Foundry Partners LLC boosted its holdings in Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares in the last quarter. Geode Capital Management LLC increased its position in Accuray by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock worth $3,924,000 after purchasing an additional 45,548 shares during the period. State Street Corp raised its stake in shares of Accuray by 3.8% during the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock worth $3,410,000 after buying an additional 70,008 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Accuray by 27.2% in the 3rd quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after buying an additional 124,459 shares during the period. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Down 0.4 %

ARAY stock opened at $2.28 on Friday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The company’s 50-day moving average price is $2.04 and its 200 day moving average price is $1.94. Accuray Incorporated has a 52 week low of $1.40 and a 52 week high of $2.95. The company has a market cap of $229.30 million, a P/E ratio of -13.41 and a beta of 1.47.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The business had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same quarter in the previous year, the company earned ($0.03) EPS. On average, research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.